Biodexa Pharmaceuticals Plc (MTP)
| Previous close | 0.3498 |
| Open | 0.3500 |
| Bid | 0.0000 x 1200 |
| Ask | 0.0000 x 3000 |
| Day's range | 0.2851 - 0.3500 |
| 52-week range | 0.2851 - 21.0000 |
| Volume | |
| Avg. volume | 977,632 |
| Market cap | 1.977M |
| Beta (5Y monthly) | 1.22 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.0600 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Bioasis Technologies Inc. Mails Management Information Circular for Annual and Special Meeting of Securityholders
NEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today announced that
- GlobeNewswire
Bioasis Technologies Inc. Announces Amendments to Arrangement Agreement with Midatech Pharma plc
NEW HAVEN, Conn., Dec. 19, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today announced the
- GlobeNewswire
Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc
US$10M Registered Direct Offering and PIPE to Strengthen Balance Sheet of Combined CompanyNEW HAVEN, Conn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central
